Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
A consultation will determine if it is appropriate for you
For the best results, a series of treatments may be recommended, typically spaced a week or two apart
Retatrutide (LY3437943) is a synthetic peptide analog designed as a triple hormone receptor agonist, targeting the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors.[1][2] It has a molecular weight of approximately 4,800 Da and is administered subcutaneously, with a half-life supporting once-weekly dosing.[3][4] Developed by Eli Lilly, it is currently in Phase 3 clinical trials for obesity and type 2 diabetes (T2D), showing potential for superior weight loss compared to existing therapies.[1][5] Key characteristics for compounding pharmacies include: Multi-Receptor Agonist : Combines actions of GIP, GLP-1, and glucagon for enhanced metabolic effects.[1][6] Lyophilized Form : Supplied as a stable powder for reconstitution, similar to other peptides.[7][8] Versatile Delivery : Primarily subcutaneous, but potential for customized formulations in research contexts.[7][9] This makes Retatrutide a candidate for specialized preparations in compounding settings, though regulatory restrictions apply
The metabolic events most closely associated with AD include insulin resistance, hyperglycemia, lipid dysregulation, mitochondrial dysfunction, and oxidative stress
US$ 22.59
US$ 21.73
US$ 23.31
US$ 22.86
US$ 27.69
US$ 22.75
